Article

China's National Medical Products Administration (NMPA) has suspended the import, sale, and use of Sun Pharma's rivastigmine hydrogen tartrate capsules following a remote inspection that revealed deficiencies in production quality management and contamination prevention. The inspection, conducted on January 26, found the quality management team lacked necessary capabilities for risk assessment.

Sun's manufacturing site in Dadra and Nagar Haveli, India, has faced previous regulatory issues, including warnings from the FDA in 2017 and 2024 for violations of manufacturing standards. Concurrently, NMPA has also inspected Supriya Lifescience, banning its chlorpheniramine maleate raw material due to inadequate management.